Literature DB >> 11533180

High resistance of human parainfluenza type 2 virus protein-expressing cells to the antiviral and anti-cell proliferative activities of alpha/beta interferons: cysteine-rich V-specific domain is required for high resistance to the interferons.

M Nishio1, M Tsurudome, M Ito, M Kawano, H Komada, Y Ito.   

Abstract

Human parainfluenza type 2 virus (hPIV-2)-infected HeLa (HeLa-CA) cells and hPIV-2 V-expressing HeLa (HeLa-V) cells show high resistance to alpha/beta interferons (IFN-alpha/beta) irrespective of whether vesicular stomatitis virus or Sindbis virus is used as a challenge virus. When Sindbis virus is used, these cells show high susceptibility to human IFN-gamma. Furthermore, the multiplication of HeLa-V cells is not inhibited by IFN-alpha/beta. HeLa cells expressing the N-terminally truncated V protein show resistance to IFN-alpha/beta, showing that the IFN resistance determinant maps to the cysteine-rich V-specific domain. A complete defect of Stat2 is found in HeLa-CA and HeLa-V cells, whereas the levels of Stat1 expression are not significantly different among HeLa, HeLa-CA, HeLa-P, and HeLa-V cells, indicating that IFN-alpha/beta resistance of HeLa-CA and HeLa-V cells is due to a defect of Stat2. HeLa-SV41V cells show high resistance to all IFNs, and no expression of Stat1 can be detected. Stat2 mRNA is fully detected in HeLa-V cells. Stat2 was scarcely pulse-labeled in the HeLa-V cells, indicating that synthesis of Stat2 is suppressed or Stat2 is very rapidly degraded in HeLa-V cells. The V protein suppresses the in vitro translation of Stat2 mRNA more extensively than that of Stat1 mRNA. An extremely small amount of Stat2 can be detected in HeLa-V cells treated with proteasome inhibitors. The half-life of Stat2 is approximately 3.5 and 2 h in uninfected and hPIV-2-infected HeLa cells, respectively. This study shows that synthesis of Stat2 may be suppressed and Stat2 degradation is also enhanced in hPIV-2-infected HeLa and HeLa-V cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533180      PMCID: PMC114485          DOI: 10.1128/JVI.75.19.9165-9176.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain.

Authors:  M Kawano; M Kaito; Y Kozuka; H Komada; N Noda; K Nanba; M Tsurudome; M Ito; M Nishio; Y Ito
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

2.  Interferon action III. The rate of primary transcription of vesicular stomatitis virus is inhibited by interferon action.

Authors:  P I Marcus; M J Sekellick
Journal:  J Gen Virol       Date:  1978-03       Impact factor: 3.891

3.  Interferon production in L cells persistently infected with hemagglutinating virus of Japan (HVJ).

Authors:  Y Ito; Y Nishiyama; K Shimokata; Y Kimura; I Nagata; A Kunii
Journal:  Virology       Date:  1976-06       Impact factor: 3.616

4.  Growth of Newcastle disease virus in a HVJ carrier culture of HeLa cells.

Authors:  K Maeno; S Yoshii; I Nagata; T Matsumoto
Journal:  Virology       Date:  1966-06       Impact factor: 3.616

5.  The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation.

Authors:  L Didcock; D F Young; S Goodbourn; R E Randall
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Sendai virus blocks alpha interferon signaling to signal transducers and activators of transcription.

Authors:  T Komatsu; K Takeuchi; J Yokoo; Y Tanaka; B Gotoh
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  A recombinant newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos.

Authors:  T Mebatsion; S Verstegen; L T De Vaan; A Römer-Oberdörfer; C C Schrier
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Isolation of monoclonal antibodies directed against the V protein of human parainfluenza virus type 2 and localization of the V protein in virus-infected cells.

Authors:  M Nishio; M Tsurudome; M Ito; M Kawano; S Kusagawa; H Komada; Y Ito
Journal:  Med Microbiol Immunol       Date:  1999-11       Impact factor: 3.402

9.  Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response.

Authors:  D F Young; L Didcock; S Goodbourn; R E Randall
Journal:  Virology       Date:  2000-04-10       Impact factor: 3.616

10.  Inhibition of interferon by an infection with parainfluenza virus type 3 (PIV-3).

Authors:  S HERMODSSON
Journal:  Virology       Date:  1963-06       Impact factor: 3.616

View more
  36 in total

1.  Identification of the nuclear export signal and STAT-binding domains of the Nipah virus V protein reveals mechanisms underlying interferon evasion.

Authors:  Jason J Rodriguez; Cristian D Cruz; Curt M Horvath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively.

Authors:  Megan L Shaw; Adolfo García-Sastre; Peter Palese; Christopher F Basler
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Importance of the anti-interferon capacity of Sendai virus C protein for pathogenicity in mice.

Authors:  Atsushi Kato; Katsuhiro Kiyotani; Toru Kubota; Tetsuya Yoshida; Masato Tashiro; Yoshiyuki Nagai
Journal:  J Virol       Date:  2007-01-10       Impact factor: 5.103

4.  Identification of paramyxovirus V protein residues essential for STAT protein degradation and promotion of virus replication.

Authors:  Machiko Nishio; Masato Tsurudome; Morihiro Ito; Dominique Garcin; Daniel Kolakofsky; Yasuhiko Ito
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Naturally occurring substitutions in the P/V gene convert the noncytopathic paramyxovirus simian virus 5 into a virus that induces alpha/beta interferon synthesis and cell death.

Authors:  Elizabeth K Wansley; Griffith D Parks
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.

Authors:  Anne Schaap-Nutt; Margaret A Scull; Alexander C Schmidt; Brian R Murphy; Raymond J Pickles
Journal:  Vaccine       Date:  2010-02-20       Impact factor: 3.641

7.  Human parainfluenza virus type 2 V protein inhibits TRAF6-mediated ubiquitination of IRF7 to prevent TLR7- and TLR9-dependent interferon induction.

Authors:  Yoshinori Kitagawa; Mayu Yamaguchi; Min Zhou; Machiko Nishio; Masae Itoh; Bin Gotoh
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

8.  Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist.

Authors:  Zhuhui Huang; Sateesh Krishnamurthy; Aruna Panda; Siba K Samal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  The amino-terminal half of Sendai virus C protein is not responsible for either counteracting the antiviral action of interferons or down-regulating viral RNA synthesis.

Authors:  Atsushi Kato; Yukano Ohnishi; Michiko Hishiyama; Masayoshi Kohase; Sakura Saito; Masato Tashiro; Yoshiyuki Nagai
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.

Authors:  Anne Schaap-Nutt; Christopher D'Angelo; Margaret A Scull; Emerito Amaro-Carambot; Machiko Nishio; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Virology       Date:  2009-12-07       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.